sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_1040> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_1040> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB11581> ;
    a rdf:Statement ;
    rdfs:label "venclexta is a bcl 2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll 1 1 in combination with azacitidine or decitabine or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia aml in adults who are age 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy 1 2 venclexta is indicated for the treatment of adult patients with chronic lymphocytic leukemia cll or small lymphocytic lymphoma sll venclexta is indicated in combination with azacitidine or decitabine or low dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia aml in adults who are age 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy this indication is approved under accelerated approval based on response rates see clinical studies 14 2" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB11581> bl:category bl:Drug .
}